News

Deals & Cases

CHF 12.5 Million financing round in Alentis Therapeutics AG

1 May 2019 – Walder Wyss advises BiomedPartners AG and BB Pureos Bioventures as Co-Lead Investors in connection with Alentis Therapeutics AG’s Series A Financing Round in the amount of CHF 12.5 mio. Alentis develops novel therapeutics in advanced liver disease and cancer. The Financing Round was further subscribed by BPI France, Schroder Adveq and the German High-Tech Gründerfonds..

The Walder Wyss team comprises Alexander Gutmans (Partner, Corporate/Venture Capital), Robert von Rosen (Partner, Corporate/M&A), Vanessa C. Haubensak (Associate, Corporate/M&A) and Manuel Bigler (Associate, IP/IT).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

News

CHF 12.5 Million financing round in Alentis Therapeutics AG

We use cookies